XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB

Across many cancer types in adults, upregulation of the nuclear-to-cytoplasmic transport protein Exportin-1 (XPO1) correlates with poor outcome and responsiveness to selinexor, an FDA-approved XPO1 inhibitor. Similar data are emerging in childhood cancers, for which selinexor is being evaluated in e...

Descripción completa

Detalles Bibliográficos
Autores principales: Galinski, Basia, Luxemburg, Marcus, Landesman, Yosef, Pawel, Bruce, Johnson, Katherine J., Master, Stephen R., Freeman, Kevin W., Loeb, David M., Hébert, Jean M., Weiser, Daniel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131731/
https://www.ncbi.nlm.nih.gov/pubmed/33975179
http://dx.doi.org/10.1016/j.tranon.2021.101114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131731/
https://www.ncbi.nlm.nih.gov/pubmed/33975179
http://dx.doi.org/10.1016/j.tranon.2021.101114

Ejemplares similares